About this trial
Opioids analgesic are the gold standard for intraoperative pain management. Their short- and long-term adverse effect motivate anesthesiologists to explore opioid sparing strategies. Dexmedetomidine is a highly selective α2 adrenergic receptor agonist that could help minimize opioid consumption both intraoperative and postoperative due to its sedative, analgesic and sympatholytic properties. This new randomized controlled trial (RCT) will answer the question whether an intraoperative dexmedetomidine infusion compared to placebo has a clinically significant impact on intraoperative remifentanil consumption during a laparoscopic abdominal elective surgery.
Eligibility criteria
Qualifiers
ASA 1-3
Laparascopic surgery (including general surgery, gynecology, urology) a small abdominal incision (less than 5 cm) will be tolerated.
Disqualifiers
Patient refusal
Chronic use of opioids
Allergy to medication used in the trial
Pregnant or breastfeeding women
Trial design
Treatments tested in this trial
- Dexmedetomidine
- Placebo
Treatment groups
Sponsors and collaborators
Ciusss de L'Est de l'Île de Montréal
Lead sponsor
Maisonneuve-Rosemont Hospital
Sponsor institution